Sanofi says FDA approves Sarclisa Escena subcutaneous formulation via portable injector
PUBT · 6d ago
Share
Listen to the news
- FDA cleared Sarclisa Escena, a subcutaneous version of Sarclisa, across all existing US multiple myeloma indications for the IV formulation.
- Launch features Enable Injections’ CirCLIQ wearable injector, billed as the first US cancer therapy delivered via a portable injector.
- Phase 3 IRAKLIA showed non-inferior efficacy versus IV, with fewer systemic administration reactions (1.5% vs 25%).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607100834OMX_____CNEWS_FR_GNW1001212222_fr) on July 10, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved